# Late effects after a stem cell transplant

Source: https://onco.cc/technologies/rejuv-tx-late-effects-overview/  
OnCo record `rejuv-tx-late-effects-overview` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

There are now around half a million people alive worldwide who have had a blood or marrow transplant. Most of them have at least one lasting health problem from it, and many have several. The list is long and reads heavily, but almost every item on it is either preventable or detectable early, which is the reason to know what is on it rather than to avoid knowing.

## Summary

A review of late effects after blood and marrow transplantation opens with the scale: advances in transplantation have reduced early transplant-related mortality and widened who can be transplanted, so management of late effects matters for a growing number of long-term survivors estimated at half a million worldwide. It names the territory: diseases of the cardiovascular, pulmonary and endocrine systems, dysfunction of the thyroid gland, gonads, liver and kidneys, infertility, iron overload, bone diseases, infection, solid cancer and neuropsychological effects. The leading causes of late mortality it lists are recurrent malignancy, lung disease, infection, secondary cancers and chronic graft-versus-host disease.

The structure underneath that list is worth stating plainly, because it determines what can be done. Late effects after transplant have four sources, and most problems have more than one.

The disease and the treatment before transplant. Anthracyclines given years earlier, radiotherapy fields, and the cumulative alkylating agent dose all arrive at the transplant already spent. A cardiovascular risk model built in 1,828 transplant recipients and validated in a second cohort of 580 used age, anthracycline dose, chest radiation, hypertension, diabetes and smoking, and reached an area under the curve of 0.74 for cardiovascular disease: three of its six variables are pre-transplant exposures.

The conditioning. Total body irradiation accounts for a disproportionate share of what follows: cataract, second solid cancers in those irradiated young, thyroid and gonadal failure, renal impairment, and the body composition changes behind later metabolic disease. Chemotherapy-only conditioning avoids some of these and brings others.

Chronic GvHD and its treatment. Chronic GvHD is itself a late effect, and the years of corticosteroids and other immunosuppression it requires produce bone loss, avascular necrosis, cataract, diabetes, muscle loss and infection. Chronic GvHD was an independent risk factor for solid cancers in the largest registry study, and active chronic GvHD carried a hazard ratio of 4.0 (95 per cent CI 1.1 to 14.7) for cardiovascular death in a 1,379-patient cohort.

A lastingly altered immune system. Covered in its own records below: altered reconstitution, lost vaccine memory, and the infection risk that follows.

The international societies published updated screening and preventive practice recommendations for long-term survivors covering both autologous and allogeneic transplant and both adults and children. The point of that document is that nearly every item on the list above has a scheduled test, a modifiable risk factor or both, so the right response to a long list is a schedule rather than alarm. The records that follow take the items one at a time: the survival curves, second cancers, iron overload, bone, eyes, kidneys and lungs, and the endocrine and cardiometabolic cluster.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Also known as: transplant late effects; post-transplant survivorship; long-term complications of HSCT
- Tags: rejuvenation; survivorship; transplant; late-effects
- Principle: A transplant compresses several distinct injuries into a few weeks: cytotoxic conditioning, total body irradiation in many regimens, a period of profound immune deficiency, and in allogeneic recipients a permanent alloimmune relationship with a new immune system. Each injures stem and progenitor pools, endothelium, endocrine glands and epithelium. Late effects are the slow expression of that damage, which is why they emerge over years and why risk does not plateau.
- Strengths: The late effects are catalogued and the screening schedule is published; Most items are either preventable, modifiable or detectable before they cause harm; Risk prediction models exist for the cardiovascular cluster and perform reasonably on validation; Survival after transplant has improved, which is why this list matters at all
- Limitations: Most survivors have at least one chronic health condition attributable to the transplant; Risk does not return to that of the general population, and for solid cancers it rises with time; Follow-up depends on someone owning it, and transplant centres are often far from where people live; Much of the long-term data comes from older conditioning regimens and may not describe current practice

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation
- Inamoto and Lee, Late effects of blood and marrow transplantation (Haematologica 2017): https://doi.org/10.3324/haematol.2016.150250
- Majhail et al., Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Biol Blood Marrow Transplant 2012): https://doi.org/10.1016/j.bbmt.2011.12.519
- Armenian et al., Prediction of cardiovascular disease among hematopoietic cell transplantation survivors (Blood Adv 2018): https://doi.org/10.1182/bloodadvances.2018019117
- Chow et al., Late cardiovascular complications after hematopoietic cell transplantation (Biol Blood Marrow Transplant 2014): https://doi.org/10.1016/j.bbmt.2014.02.012
- Rizzo et al., Solid cancers after allogeneic hematopoietic cell transplantation (Blood 2009): https://doi.org/10.1182/blood-2008-05-158782

## Connected records

- technologies: [After a transplant or cell therapy: what to ask for](https://onco.cc/technologies/rejuv-tx-what-to-ask-for/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Bone, eyes, kidneys and lungs after transplant](https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/), [Chronic graft-versus-host disease](https://onco.cc/technologies/gvhd-chronic-overview/), [Fertility, growth and what total body irradiation costs](https://onco.cc/technologies/rejuv-tx-fertility-and-growth/), [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [Hormones, metabolism and the heart after transplant](https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/), [Iron overload after transplant](https://onco.cc/technologies/rejuv-tx-iron-overload/), [Quality of life after transplant and cell therapy](https://onco.cc/technologies/rejuv-tx-quality-of-life/), [Second cancers after allogeneic transplant](https://onco.cc/technologies/rejuv-tx-second-cancers/), [Survival after transplant, and why the curve never quite rejoins the population](https://onco.cc/technologies/rejuv-tx-survival-after-transplant/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Total body and total marrow irradiation](https://onco.cc/technologies/total-body-irradiation/), [Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered](https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- terms: [Conditioning regimen (myeloablative, reduced-intensity)](https://onco.cc/terms/conditioning-regimen/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Quality of life](https://onco.cc/terms/quality-of-life/), [Secondary malignancy (therapy-related cancer)](https://onco.cc/terms/secondary-malignancy/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- roadmaps: [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/)
- trials: [AlloCare: a stepped-care late-effects service after allogeneic transplant](https://onco.cc/trials/rejuv-trial-allocare/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-tx-late-effects-overview.json